Torrey Pines Investment Biotech Investor Pharmaceutical Drug Development Start-Ups HDAC-inhibitors CD20 CD16 conjugates CNS AVN 211 lymphoma gosogliptin quisinostat virio HIV HBV Altzheimer Schizophrenia drug formulations CRO pre-clinical clinical

TORREY PINES
INVESTMENT

News About Us Portfolio Team Contacts

ChemDiv and Abbott expand collaboration to develop branded generic pharmaceuticals for high growth emerging markets

Tensha Therapeutics To Be Acquired By Roche

ChemDiv Announces Achievement of a Development Milestone in a Drug Discovery Collaboration With Janssen

BioIntegrator Announced Launch of Neskler® -- a Generic of Novartis MS Blockbuster Gilenya® in Emerging Markets

J.P. Morgan 34th Annual Healthcare Conference

Viriom presented the results of the safety and antiviral effect of its novel drug Elpida® at the EACS-2015 conference in Barcelona

Avineuro LLC  advances its highly selective 5-HT6R antagonist program in Alzheimer Disease

TeaRx launches an innovative anticoagulant Tearexaban

Ron Demuth Interviewed for Nature Drug Discovery News Article

Avelas Biosciences Completes 7.4M Funding

T23 Announces Global License of SCRIPPS’ CD22 Siglec Oncoimmunological Platform for B-cell Tumors

Viriom is Expanding its Portfolio of Novel Antiviral Drugs

ChemRar HighTech Center is featured in Pharmaceutical Executive article “Russia’s Bet on Biopharma”

 

 

Current Portfolio
TPI and ChemRar

TORREY PINES
INVESTMENT

6605 Nancy Ridge Drive, Ste 207, San Diego CA 92121
T: (858) 724-0581   F: (858) 345-3761
News About Us Portfolio Team Contacts